An active surveillance and early warning system for drug-induced diseases

Abstract

The invention relates to an active monitoring and early warning system for drug-induced diseases, which is used for monitoring the clinical treatment process information of patients, grading and early warning of drug adverse events and medication errors, and actively reporting; It is comprehensively obtained from the results of the patient’s drug risk assessment and the monitored drug risk information; at the same time, based on the information of the patient’s treatment process, the monitoring is continued forward and backward, and the correlation between the adverse reaction and the suspicious drug is determined. Actively report drug adverse events, effectively prevent drug risks, and improve the reporting rate and accuracy of adverse events.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to an active monitoring and early warning system for drug-induced diseases. Background technique [0002] Adverse drug events (ADEs) and medication errors (ME) are one of the main causes of drug-induced diseases. Important measures of institutional adverse event rates. The current main ADE monitoring methods include adverse event medical record review method and voluntary reporting system method. The occurrence of ADE is collected through medical record review and voluntary reporting. The number and quality of reports and signal detection capabilities of this method depend on medical institutions. Reporting awareness and cooperation, there are problems such as false positives, missed negatives, and post-event reporting, which cannot reflect the true occurrence level of ADE or ME, and the current ADE monitoring is "post-event" passive monitoring, lacking in advance prevention. [...

AI Technical Summary

Problems solved by technology

[0004] 1. The current ADE / ME monitoring system has problems such as false positives, missed negatives, low reporting rate, low reporting accuracy, and inconsistent evaluation standards for the correlation between suspicious drugs and adverse events, so it cannot reflect the true occurrence level of ADE or ME. This further resulted in the small sample size, low sample quality and poor timeliness of the raw data of adverse drug event research, which brought inconvenience to clinical drug safety supervision and drug quality feedback

[0005] 2. Some ADE / ME can be avoided or discovered at an early stage, but the current ADE / ME monitoring system is mostly for post-event treatment and lacks an early warning mechanism. The lack of early warning makes clinical treatment miss the best time to intervene in ADE, increasing the Incidence and severity of ADEs

[0006] 3. ADE reporting requires accuracy and needs a certain amount of time to be evidence-based, while ADE early warning requires timeliness and early warning of potential ADE risks. The current ADE / ME monitoring system is difficult to simultaneously meet the requirements of accurate reporting and timely early warning

Images